

## CENTRO DE INVESTIGACION EN SANIDAD ANIMAL (CISA-INIA)

European Union Reference Laboratory for ASF, (EURL-ASF)

Centro de Investigación en Sanidad Animal  
CISA-INIA, Valdeolmos 28130, Madrid, Spain.

**Contact people**

Dr. Carmina Gallardo  
Virginia Pelayo

E-mail: [eurl.asf@inia.es](mailto:eurl.asf@inia.es)



## SOP/CISA/ASF/VI/2

PROCEDURE FOR AFRICAN SWINE FEVER VIRUS (ASFV)  
ISOLATION ON PORCINE ALVEOLAR MACROPHAGES  
AND HEMADSORPTION TEST.

### CONTENTS

1.	PURPOSE.
2.	SCOPE.
3.	REFERENCES.
3.1.	DOCUMENTS USED IN THE PROCEDURE REDACTION.
3.2.	COMPLEMENTARY DOCUMENTS (SOPs) TO BE USED.
4.	BACKGROUND INFORMATION.
5.	PROCEDURE DESCRIPTION.
5.1.	EQUIPMENT AND MATERIALS.
5.2.	PREPARATION.
5.3.	METHODS.
5.4.	ANALYSIS AND INTERPRETATION OF THE RESULTS.
5.5.	CRITICAL POINTS.
5.5.	SAFETY CAUTIONS

## 1. PURPOSE

The main goal of this procedure is to describe the African swine fever virus (ASFV) virus isolation in porcine leukocytes and the hemadsorption.

*Currently this technique is included in the Chapter 2.8.1. of the Manual of Diagnostic Tests and Vaccines for Terrestrial Animals 2012 Edition.*

## 2. SCOPE

This procedure is applicable to porcine clinical samples such as blood with anticoagulant, sera and ASF target porcine tissues, as well as to homogenate soft ticks.

## 3. REFERENCES

### 3.1. DOCUMENTS USED IN THE PROCEDURE REDACTION

As a basic reference for the elaboration of this procedure the criteria established in the next documents have been taken:

1. AFRICAN SWINE FEVER. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (mammals, birds and bees). CHAPTER 2.8.1. OIE, 2012 [[http://www.oie.int/fileadmin/Home/eng/Health\\_standards/tahm/2.08.01\\_ASF.pdf](http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.08.01_ASF.pdf)]
2. Carnero R., Larenaudie, B., Ruiz-Gonzalvo, F. y Haag, J. (1967). "Peste porcine africaine. Etudes sur la reaction d'hemadsorption et son inhibition par des anticorps specifiques". Rec. Vet. Med. 143, 49-59.
3. Carrasco L., de Lara FC, Martin de las Mulas J, Gomez-Villamandos JC, Hervas J, Wilkinson PJ, Sierra MA . (1996a). "Virus association with lymphocytes in acute African swine fever". Vet Res;27(3):305-12
4. Carrascosa AL, Bustos MJ, de Leon P. "Methods for growing and titrating African swine fever virus: field and laboratory samples". Curr Protoc Cell Biol. 2011 Dec;Chapter 26: Unit 26.14.

5. Galindo I, Almazan F, Bustos MJ, Viñuela E, Carrascosa AL. (2000). "African swine fever virus EP153R open reading frame encodes a glycoprotein involved in the hemadsorption of infected cells". Virology Jan 20;266(2):340-51.
6. Malmquist, W. y Hay, D. (1960). "Hemadsorption and cytopathic effect produced by African swine fever virus in swine bone marrow and buffy coat cultures". Am. J. Vet. Res. 21, 104-108.

### ASF REVIEWS:

1. Arias, M., Sánchez-Vizcaíno, J.M. (2012). African swine fever. In: Zimmerman, J., Karriker, L.A., Ramirez, A., Schwartz, K.J, Stevenson, G.W. (Eds), Diseases of swine, 10th Edition. John Wiley and Sons, United States of America, pp. 396-404.
2. Arias, M.; Sánchez, C.; González, M.A.; Carrasco, L. y Sánchez-Vizcaíno, J.M. (2002). "Peste porcina Africana" In "Curso digital de enfermedades infecciosas porcinas". On line, July, 2002. [<http://www.sanidadanimal.info/cursos/curso/7/7-ppa.htm>]
3. Food and Agriculture Organization of the United Nations (FAO). RECOGNIZING AFRICAN SWINE FEVER. A FIELD MANUAL. 2000 Edition. [<http://www.fao.org/docrep/004/X8060E/X8060E00.HTM>]

### 3.2. COMPLEMENTARY DOCUMENTS (SOPs) TO BE USED.

- Procedure of samples processing for African swine fever (ASF) diagnosis (**SOP/CISA/SAMPLE/1**).
- Procedure for the extraction of African Swine Fever Virus (ASFV) DNA (**SOP/CISA/ASF/DNA EXTRACTION/1**).
- Procedure for the detection of African Swine Fever Virus (ASFV) by conventional polymerase chain reaction (PCR) (**SOP/CISA/ASF/PCR/1**).
- Procedure for the detection of African Swine Fever Virus (ASFV) by real time polymerase chain reaction (PCR) (**SOP/CISA/ASF/PCR/2**).

## 4. BACKGROUND INFORMATION

### 4.1. ABBREVIATION

ASF: African swine fever

ASFV: African swine fever virus  
H.A.D: haemadsorption  
C.E.P: cytopathic effect  
MAP: porcine alveolar macrophages  
PC: ASFV isolate positive control  
NC: Negative control  
r.p.m: revolutions per minute  
PCR: Polymerase chain reaction  
DIFT: Direct immunofluorescence tests.


## 4.2. BACKGROUND

Malmquist and Hay made one of the most important advances in the study of African swine fever virus (ASFV) in 1960 demonstrating that ASFV was able to infect and replicates in primary leukocyte cultures from pig peripheral blood. Virus isolation is based on the inoculation of sample material on susceptible primary cell cultures of porcine origin, monocytes and macrophages cells. If the ASF virus is present in the sample, it will replicate in the cells and the **cytopathic effect (C.P.E)** will be produced in the infected cells.

When the virus replicates in these cultures, the majority of the ASFV strains produced the **haemadsorption reaction (HAD)** due to adsorption of pig red blood cells on ASFV infected leukocytes. Cell lysis and C.P.E. usually occurs after 48-49 hours of haemadsorption. The importance of this finding relies on its specificity because none of the other pig viruses are capable of haemadsorbing in leukocyte cultures.

The **phenomenon of HAD** is linked to two different genes of the ASFV genome. The ORF *EP402R* and ORF *EP153R* of Spanish isolate BA71VR ASFV isolate (*GenBank accession no. ASU18466*). The first gene encodes a protein homologous to CD2, the cell adhesion receptor of T cells and an immune response modulator, and the second one encodes a protein homologous to CD44 molecules, involved in cellular adhesion and T-cell activation. In the case of

the *EP402R* gene is responsible for the adhesion of swine erythrocytes to infected cells, and the *EP153R* is as a stabilizer of this adhesion.



Virus isolation and identification by HAD are recommended as a **reference test for the confirmation of positive results of a prior antigen ELISA, Polymerase chain reaction (PCR) or Direct immunofluorescence tests (DIFT)**. They are also recommended when ASF has already been confirmed by other methods, particularly in **case of a primary outbreak or case of ASF**.

## 5. DESCRIPTION

### 5.1. EQUIPMENT AND MATERIALS

#### MATERIALS

- Analytical Balance.
- Adsorbent paper.
- Chronometer.
- Centrifuge [SORVALL RC6 rotor SLA 1500 or similar characteristics].
- Centrifuge tubes 250 ml [SORVALL or similar characteristics].

- CO<sub>2</sub> (±0.5%) Incubator/ 37±3°C.
- Counter chamber [THOMA or NEUBAUER or similar characteristics].
- Cryotubes.
- Eppendorff tubes 0.5, 1.5 y 2 ml.
- Freezer <-10 °C.
- Freezer <-70 °C.
- Fridge 4±3°C.
- Glass or plastic pipettes for volume of 1-25 ml.
- Latex or nitrile gloves.
- Laminar flow cabin class II.
- Liquide Nitrogen Container.
- 96 well cell culture plate's bottom flat [NUCLONTM "Surface, NUNC or similar characteristics].
- Micropipette disposable sterile tips of 1-20, 20-200 and 200-1000 µl.
- Multichannel pipette 5-50µl.
- Multichannel pipette 50-300 µl.
- Phase Contrast Inverted cell Culture Microscope.
- Ph meter (0.01 UpH).
- Pipetboy acu or equivalent.
- Reagent reservoir Polystyrene 50 ml.
- Shaker incubator 37±2°C.
- Single channel pipettes 1-10 µl.
- Single channel pipettes 10-100 µl.
- Single channel pipettes 10-200µl.
- Single channel pipettes 200-1000µl.
- Sterile conic plastic tubes 12 ml and 50 ml.
- Sterile funnel.
- Sterile glass bottle 250ml and 500 ml.
- Sterile forceps.
- Sterile scalpel.
- Sterile scissors.
- Table centrifuge Megafuge 1.OR [rotor Heraeus #7570 or similar characteristics].

- Vortex.

## REAGENTS.

- **Ammonium Chloride NH<sub>4</sub>Cl** [Ref.: 1.01145.1000 (Merck) or similar characteristics] *Store at room temperature.*
- **Citric acid monohydrate** [Ref.: 1.00244.1000 (Merck) or similar characteristics] *Store at room temperature.*
- **Dihydrogénophosphate de potassium (PO<sub>4</sub>H<sub>2</sub>K)** [Ref. 1.04873.1000 (MERCK) or similar characteristics]. *Store at room temperature.*
- **Dimetil sulfóxide (DMSO)** [Ref.: 10002430 (Bio-Rad) or similar characteristics]. *Store at room temperature.*
- **Gentamicin sulfate 50mg/ml** [Ref.: 17-518Z (BioWhittaker) or similar characteristics]. *Store at 4±3°C.*
- **Glucose** [Ref.: 1.08342.1000 (Merck) or similar characteristics]. *Store at room temperature*
- **Glutamine [4mM]** [Ref.: BE17-605E (BioWhittaker)] or similar characteristics]. *Store <-10 °C.*
- **Serum Fetal Bovine (SFB)** [Ref.: 10106-169 (Gibco) or similar characteristics]. *Store <-10 °C.*
- **Non-essential amino acid solution 100x** [Ref.: BE13-114E (BioWhittaker) or similar characteristics]. *Store at 4±3°C.*
- **Na Pyruvate** [Ref.: BE13-115E (BioWhittaker) or similar characteristics]. *Store at 4±3°C.*
- **Nystatine [10.000 U/ml]** [Ref.: 15340029 (Gibco) or similar characteristics]. *Store <-10 °C*
- **RPMI 1640 cell culture medium** [Ref.: BE12-167F (BioWhittaker) or similar characteristics]. *Store at 4±3°C*
- **Phosphate buffered saline (PBS 1x) in tablets** [Ref.: 524650-1 (CALBIOCHEM) or similar characteristics]. *Store at room temperature.*
- **Potassium Chloride (ClK)** [Ref. 1.04936.0500 (MERCK) or similar characteristics] *Store at room temperature.*
- **Sodium Chloride (ClNa)** [Ref. 1.06404.1000 (MERCK) or similar characteristics] *Store at room temperature.*
- **Sodium phosphate (PO<sub>4</sub>HNa<sub>2</sub>)** [Ref. 1.06586.0500 (MERCK) or similar characteristics] *Store at room temperature.*

- **Trisodic citrate di-hydrate** [Ref.: 1.06448.1000 (Merck) or similar characteristics] *Store at room temperature.*
- **Türk's colorant.** [Ref.: 1.09277.0500 (Merck) or similar characteristics]. *Store at room temperature.*
- **PC:** ASFV positive HAD isolate. *Store at  $\leq -70^{\circ}C$*

- **Phosphate buffered saline (PBS 1x) pH 7.2** ( $\pm 0.2$  U<sub>pH</sub>) → The PBS could be obtained in tablets or could be prepared as follows:

ClNa	-----	8.0 gr ( $\pm 0.1$ )
ClK	-----	0.2 gr ( $\pm 0.01$ )
PO <sub>4</sub> H <sub>2</sub> K	-----	0.2 gr ( $\pm 0.01$ )
PO <sub>4</sub> HNa <sub>2</sub>	-----	1.15 gr ( $\pm 0.05$ )
Distilled water	-----	1,000 ml

*Store at room temperature. Expiry date: 1 year.*

## 5.2. PREPARATION.

### 5.2.1. SAMPLE PREPARATION.

Sample preparation is performed according is described in the sample processing procedure for ASF diagnosis (SOP/CISA/ASF/SAMPLE/1).

### 5.2.2. REAGENTS PREPARATION.

- **Citrate-dextrose acid (ACD)**

Trisodic citrate di-hydrate	-----	11 gr ( $\pm 0.1$ )
Citric acid monohydrate	-----	4.34 gr ( $\pm 0.05$ )
Glucose	-----	13.35 gr ( $\pm 0.1$ )
Distilled H <sub>2</sub> O	-----	to 500 ml

*Sterilize by filtration and store at  $4\pm 3^{\circ}C$ . Expiry date: 1 year.*
- **Freeze solution:** Fetal Bovine Serum + 10 % Dimetil sulfóxide (DMSO). *Must be prepared just before being used.*
- **Erythrocytes lyses solution:** 0.83% Ammonium Chloride sterile → 8.3gr ( $\pm 0.1$ ) of NH<sub>4</sub>Cl in 1000 ml of distilled water. *Store at  $4\pm 3^{\circ}C$ . Expiry date: 6 months.*
- **Lung washing buffers:** PBS1 x + gentamicin sulfate 50mg/ml + 3% ACD. *Store at  $4\pm 3^{\circ}C$*
- **MAP Culture Medium:** RPMI 1640 supplemented with 20% of Serum Fetal Bovine, 1% non-essential amino acid solution 100x, 1% Na Pyruvate, 1% de glutamine [4mM], nystatine [10.000 U/ml] and gentamicin sulfate 50mg/ml. *Store:  $4\pm 3^{\circ}C$ .*

## 5.3. METHODS

### A) ALVEOLAR MACROPHAGES HARVESTING AND CULTURE.

**Harvesting of alveolar macrophages from lungs:** The MAP are obtained from lung's piglets (2-3 weeks) perfunding the lungs through bronco-alveolar washing with a washing solution described in the section 5.1 according to the following steps:


1. Close the trachea with a forceps before cutting.
2. Wash the lungs with distilled water removing the heart.
3. Put the lungs into adsorbent paper and add with and sterile funnel **500-600 ml of Washing Solution.**
4. Massage the lungs for 1-2 minutes and add the bronco-alveolar wash into a sterile bottle (**this step should be repeated twice**).
5. Distribute the bronco-alveolar wash in centrifuges tubes (SORVALL) of 250 ml
6. Centrifuge at SORVALL RC6 centrifuge [rotor SLA 1500] **4,000 r.p.m (2,500g) for 15 minutes** at room temperature.
7. Resuspend the precipitate in **50 ml of Washing Solution** and add to a sterile plastic tube of 50 ml

REV. 2013

8. Centrifuge in table centrifuge [Megafuge 1.0R rotor Heraeus #7570] **4,000 r.p.m (2,500g) for 2 minutes** at room temperature.
9. Repeat the **washing step twice**.
10. Remove the supernatant and resuspend the cell precipitate in **known volume (p.ex. 5ml) of SFB**. Count the MAP in a counter chamber THOMA, and adjust the concentration to a **final concentration of  $5 \times 10^7$  cells (MAP)/ml**

**Example:**

- ◆ 5 µl of MAP resuspend with 5 ml of porcine serum + 495 µl of Türk's colorant.
- ◆ Vortex
- ◆ 25-30 µl are put in the THOMA counter chamber



**Thoma counter chamber**

11. Distributed the resuspended cells with a **final concentration of  $5 \times 10^7$  cells (MAP)/ml** in cryotubes (1ml/cyotube), add 10% of DMSO (100µl/cryotube) and **store at  $\leq -70$  °C overnight**.
12. Keep the cryotubes at  $\leq -70$  °C overnight and store in liquid nitrogen.

**B) ALVEOLAR MACROPHAGES CULTURE.**

1. Defrost one vial containing between  $10^6$  -  $10^7$  cells/ml, at  $37 \pm 2$ °C in an incubation bath and place the cellular suspension into a 12ml steril conic plastic tubes

2. Centrifuge the cell suspension in table centrifuge [Megafuge 1.0R rotor Heraeus #7570] **2,000 r.p.m (1,050g) for 10 minutes**
3. Wash the cellular pellet with **5 ml of sterile PBS 1x** and centrifuge in table centrifuge [Megafuge 1.0R rotor Heraeus #7570] **2,000 r.p.m (1,050g) for 10 minutes** at room temperature
4. Resuspend the pellet in **10 ml of MAP Culture Medium (final concentration of  $5 \times 10^6$ )** and add 100 µl of the cell suspension into each well of a 96 well cell culture plate's bottom flat (**400,000 cells/well**).
5. Incubate the plates between 1-4 hours at  $37 \pm 2$ °C in  $\text{CO}_2$  ( $\pm 0.5\%$ ) atmosphere meanwhile the samples preparation.


**C) SAMPLE INOCULATION.**

1. After 1-4 hours inoculated the MAP with **1/10 dilution (10 µl/well) of treated sterile sample**. If it is possible inoculated at least four wells per sample.
2. Inoculated four wells with the PC and leave four wells without inoculum as cell control (negative control). Un-inoculated negative controls are essential to monitor the possibility of nonspecific HAD.
3. Add 20 µl per well of a fresh preparation of **Swine erythrocyte suspension** (1% pig erythrocytes in esterile in PBS 1x).
4. Incubate at  $37 \pm 2$ °C in  $\text{CO}_2$  ( $\pm 0.5\%$ ) incubator. **Read the plates every day for 7 days to check the presence of HAD or CPE.**

**5.4. ANALYSIS AND INTERPRETATION OF THE RESULTS.**

**NOTE:** At the moment of reading results, each well is analyzed as individual well comparing with the PC and the results obtained in the wells without inoculated. In this way, samples will be analyzed respect to the controls of its plate.

The inoculated well should be read every day in the microscope to check the presence of a **positive HAD and/or CPE**. The first read can be performed at 14-16 hours post inoculation.



To check the presence of the HAD positive results in the microscope the plates must be gently shaken allowing the read of the HAD positive results. The read period must be extended until check the presence of HAD and/or CPE positive results until 7 days.

**Haemadsorption consists** of the attachment of large numbers of pig erythrocytes to the surface of infected cells (rosette). A CPE consists in a reduction of the number of adherent cells in the absence of haemadsorption due to the cytotoxicity of the inoculum, Aujeszky's disease virus or non-haemadsorbing ASFV, which can be detected by the FAT on the cell sediment or by use of PCR. If no change is observed, or if the results of the immunofluorescence and PCR tests are negative, subinoculate the supernatant into fresh MAP cultures.

**CPE+/PCR +/ HA - → Nonhaemadsorbing ASFV**  
**CPE+/PCR -/ HA - → Cytotoxic (no ASFV)**

#### 5.4. CRITICAL POINTS

In the last years has been analyzed a lot of sample by VI, with good results of specificity and sensitivity for virological diagnosis of ASF. But there are some critical points:

1. **The procedure is long and laborious.** To give a correct ASF diagnosis it is required around 5 days if HAD pattern if observed in the first passage. If not can be delay until 15-30 days. It is not recommended as choice technique for a primary diagnosis. It is used as confirmatory technique for PCR or DIFT positive results.
2. The presence of CPE without HAD can be due to the presence of additional viruses or to a cytotoxic effect. This issue makes more difficult a correct diagnosis of the disease and requires a late PCR confirmation.
3. Previous studies have demonstrated that **badly conserved sample could origin false reaction avoiding the isolation of the ASFV**. The samples must be kept in a cold chain during the storage and transport.
4. Previous studies have demonstrated the **influence** of lyophilized samples **in the HAD technique decreasing the effectiveness**
5. This technique requires a laboratory with cell culture conditions and animal facilities department.

#### 5.5. SAFETY CAUTIONS

- Read the protocol previously.
- Work in sterile conditions to avoid the cell culture contamination.
- Avoid any reagent contamination.
- Do not eat, smoke or drink while the manipulation of reagents.
- Do not pipette by mouth.
- Use a new tip for each sample.
- Always include PC, and NC.

**Worksheet CISA/ASF/VI/**

**ID REGISTER:**

**DATE:**

**TECHNICIAN:**

**CELLS:**

**DATE CELL CULTURE:**

**DATE CELL INOCULATION:**

	1	2	3	4	5	6	7	8	9	10	11	12
<b>A</b>												PC
<b>B</b>												PC
<b>C</b>												PC
<b>D</b>												PC
<b>E</b>												NC
<b>F</b>												NC
<b>G</b>												NC
<b>H</b>												NC

**COMMENTS:**